Edward van Wezel Managing Partner

Edward is founder of BioGeneration Ventures and has extensive international expertise in pharma and biotech companies. Edward currently serves on the supervisory boards of Progentix Orthobiology, Mucosis, Cristal Therapeutics, Surgvision and Synaffix. He served on the supervisory boards of BioCeros (sold in 2011), Noviogendix (sold in 2015) and was founding investor and supervisory board member of Acerta Pharma (sold in 2015).

Edward started his industrial career as process engineer for Chiron Inc. He was project manager at Johnson & Johnson responsible for product development projects in the oncology franchise and was involved in corporate licensing activities. Since 2000 he gained experience as CEO of several early stage companies in the Netherlands.

Edward also serves on the board of Mibiton.

Edward holds a M.Sc in chemistry from the University of Utrecht and a M.Sc in biochemical engineering from the Delft University of Technology.

Telephone +31 35 - 699 3000
E-mail adress edward@biogeneration.vc
   
Desktop versie